213013-97-9

Upstream product

• 16766-10-2 bis-(4-benzoylamino-phenyl)-disulfide 
• 722-27-0 bis(4-aminophenyl)disulfide 
• 98-88-4 benzoyl chloride 
• 1193-02-8 4-aminotiophenol 
• 112308-01-7 S-dimethylcarbamoyl-p-aminothiophenol 
• 91827-26-8 N-benzoyl-S-dimethylcarbamoyl-p-aminothiophenol 

Downstream Products

• 321586-66-7 2-[[[4-(Benzoylamino)phenyl]sulfanyl]methyl]acrylic acid 
• 1258424-23-5 C₂₅H₂₆N₈OS₂ 
• 1258424-24-6 C₂₅H₂₆N₈OS₂ 
• 1258425-82-9 C₂₃H₂₁N₇OS 
• 100865-41-6 benzoic acid-[4-(trans-2-chloro-ethenesulfonyl)-anilide] 
• 100865-32-5 benzoic acid-[4-(trans-2-chloro-vinylmercapto)-anilide] 
• 16766-10-2 bis-(4-benzoylamino-phenyl)-disulfide 
• 100398-35-4 4-benzoylamino-benzenesulfenyl chloride 

Relevant academic research and scientific papers

TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS

Compounds of the formula (I) and formula (II) and pharmaceutically acceptable salts thereof.

PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND METHODS OF TREATING KINASE-ASSOCIATED CONDITIONS THEREWITH

The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one ki

QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY

Compounds of formula (IA) or (IB), are inhibitors of aurora kinase activity: Formula (IA), (IB) wherein -L1Y1-[CH2]z- is a linker radical wherein Y1, L1 and z are as defined in the claims; R6 is C1-C4alkoxy, hydrogen or halo; W represents a bond, -CH2-, -O-, -S-, -S(=O)2-, or -NR5- where R5 is hydrogen or C1-C4 alkyl; Q is =N-, =CH- or =C(X1)- wherein X1 is cyano, cyclopropyl or halo; linker radicals L2 are as defined in the claims; R is a radical of formula (X) or (Y): wherein R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R4 is hydrogen; or optionally substituted C1-C6 alkyl, C3-C7 cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, heteroaryl(C1-C6 alkyl)-, -(C=O)R3, -(C=O)OR3, or -(C=O)NR3 wherein R3 is hydrogen or optionally substituted (C1-C6)alkyl, C3-C7 cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, or heteroaryl(C1-C6 alkyl)-; R41 is hydrogen or optionally substituted C1-C6 alkyl; and D is a monocyclic heterocyclic ring of 5 or 6 ring atoms.

3-Arylsulfonyl-2 (substituted methyl) propanoic acid derivatives as matrix metalloproteinase inhibitors

Compounds which are 3-arylsulfonyl-2-methyl propanoic acid derivatives of formula (I): wherein X is HO—NH— or HO—, R1 is selected from phenyl, 4-chlorophenyl, 4-florophenyl, 4-cyanophenyl, benzamido (i.e., —NH—CO-Ph) and benzamido substituted on the terminal phenyl ring by C1-C4alkyl, fluoro, chloro, cyano or C1-4alkoxy; R2is selected from (a) —S—Ar or —S—CH2—Ar wherein Ar is an aromatic moiety; (b) —O—Ar wherein Ar is as defined above; (c) —S-Het or —S—CH2-Het wherein Het is a heterocyclic ring; and (d) 2,5-dioxo-1-imidazolidinyl or 2,4-dioxo-1-imidazolinyl; and the pharmaceutically acceptable salts thereof; have potent and selective inhibitory activity against matrix metalloproteinases (MMPs) and can thus be used in the treatment and prevention of diseases mediated by MMPs.

THERMAL REARRANGEMENT OF O-THIOACYL DERIVATIVES OF N-ACYL-N-ARYLHYDROXYLAMINES

The ability of the Ar-N-O-C=S system of atoms to undergo a thermal rearrangement of the Claisen type was investigated.On the basis of the experimental data it was concluded that the process is predominantly nonconcerted in nature.